09/02/2016 23:46:51 1-888-992-3836 (toll free) Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
02/04/20168:00AMBWFDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Ag...
First and Only Intravenous NK1 Receptor Antagonist Approved in the U.S. for Use in MEC Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for single-dose EMEND® (fosaprepitant dimeglumine... More...>>
02/03/20164:13PMDJNMerck Posts Lower Revenue and Profit -- 2nd Update
By Austen Hufford and Peter Loftus Merck & Co. posted declines in sales and profit as the pharmaceutical giant gave revenue projections below analyst forecasts and earnings expectations on the lower end of them. Merck shares, which have fallen 9.5% in the last three months, fell 1% to $49.89 in recent trading. Merck... More...>>
02/03/20164:09PMDJNCorrection to Merck Earnings Story
Combined sales of Type 2 diabetes treatments Januvia and Janumet declined 12%. "Merck Revenue and Profit Falls -- Update," published at 12:38 p.m. EST, incorrectly stated that Januvia sales alone declined 12% in the eighth paragraph. The error also appeared in an earlier version of the story published at 7:51... More...>>
02/03/20161:08PMDJNMerck Revenue and Profit Falls -- Update
By Austen Hufford and Peter Loftus Merck & Co. posted declines in sales and profit as the pharmaceutical giant gave revenue projections below analyst forecasts and earnings expectations on the lower end of them. Merck shares, which have fallen 11% in the last three months, fell 2.9% to $48.95 in midday trading Wednesday... More...>>
02/03/20168:30AMDJNMerck Revenue and Profit Falls
Merck & Co. posted declines in sales and profit as the pharmaceutical giant gave revenue projections below analyst forecasts and earnings expectations on the lower end of them. Shares, which have fallen 6% in the last three months, fell 2.8% in premarket trading. Merck said it expects 2016 adjusted earnings per share... More...>>
02/03/20168:21AMDJNMerck Revenue and Profit Falls
By Austen Hufford Merck & Co. posted declines in sales and profit as the pharmaceutical giant gave revenue projections below analyst forecasts and earnings expectations on the lower end of them. Shares, which have fallen 6% in the last three months, fell 2.8% in premarket trading. Merck said it expects 2016 adjusted... More...>>
02/03/20166:45AMBWMerck Announces Fourth-Quarter and Full-Year 2015 Financial Results
Fourth-Quarter 2015 GAAP EPS was $0.35; Fourth-Quarter Non-GAAP EPS was $0.93, an Increase of 7 Percent; Full-Year 2015 GAAP EPS was $1.56; Full-Year 2015 Non-GAAP EPS was $3.59, an Increase of 3 Percent Fourth-Quarter 2015 Worldwide Sales Were $10.2 Billion, a Decrease of 3 Percent, Including a 7 Percent Negative Impact... More...>>
01/28/20169:36PMDJNFDA Approves Merck's New Hepatitis C Treatment -- 2nd Update
By Peter Loftus Merck & Co. set a list price of its new hepatitis C treatment at a discount of more than 30% off the list prices for rival drugs, in an apparent effort to compete on price. The U.S. Food and Drug Administration approved Merck & Co.'s new treatment for hepatitis C, the latest entrant in a booming... More...>>
01/28/20168:15PMDJNFDA Approves Merck's New Hepatitis C Treatment -- Update
By Peter Loftus The U.S. Food and Drug Administration approved Merck & Co.'s new treatment for hepatitis C, the latest entrant in a booming market for drugs for the viral infection--a market now dominated by Gilead Sciences Inc. Merck's treatment, Zepatier, is a once-daily, single-tablet combination of two... More...>>
01/28/20167:10PMDJNFDA Approves Merck's New Hepatitis C Treatment
The U.S. Food and Drug Administration approved Merck & Co.'s new treatment for hepatitis C, the latest entrant in a booming market for drugs for the viral infection—a market now dominated by Gilead Sciences Inc. Merck's treatment, Zepatier, is a once-daily, single-tablet combination of two drugs, grazoprevir... More...>>
01/28/20167:01PMDJNFDA Approves Merck's New Hepatitis C Treatment
By Peter Loftus The U.S. Food and Drug Administration approved Merck & Co.'s new treatment for hepatitis C, the latest entrant in a booming market for drugs for the viral infection--a market now dominated by Gilead Sciences Inc. Merck's treatment, Zepatier, is a once-daily, single-tablet combination of two... More...>>
01/28/20167:01PMPRNUSMerck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype...
Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review ZEPATIER Achieves High Cure Rates (SVR12) in Broad Range of Patients with Chronic Hepatitis C Infection, Including Those with Compensated Cirrhosis... More...>>
01/28/20166:59PMBWMerck Receives FDA Approval of ZEPATIER™ (elbasvir & grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1...
ZEPATIER Achieves High Cure Rates (SVR12) in Broad Range of Patients with Chronic Hepatitis C Infection, Including Those with Compensated Cirrhosis, Renal Impairment of Any Degree and HIV-1/HCV Co-infection Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug... More...>>
01/27/20161:49PMDJNFDA to Review Merck Antitoxin for Clostridium Difficile
Joshua Jamerson Merck & Co. said Wednesday that the U.S. Food and Drug Administration would review an investigational antitoxin that researchers hope will prevent the recurrence of an illness often passed on to patients by healthcare workers. Clostridium difficile is a bacterium that causes inflammation of the colon... More...>>
01/27/20168:30AMBWMerck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention...
FDA Grants Priority Review with Target Action Date of July 23, 2016 Marketing Authorization Application Also Filed with the European Medicines Agency Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics... More...>>
01/25/20165:00AMGLOBEAffimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA(R) (pembrolizumab) for Patients w...
HEIDELBERG, Germany, Jan. 25, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that it has entered into a clinical research collaboration in immuno-oncology with Merck (NYSE:MRK... More...>>
01/19/201610:00AMBWData for KEYTRUDA® (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers S...
Seven Registration-Enabling Trials Evaluating KEYTRUDA in Patients with Gastrointestinal Cancers are Planned or Underway Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new and updated findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy... More...>>
01/17/20169:30PMDJNSamsung Gets European Approval for Enbrel Copy
SEOUL—Samsung Group said it has won approval from regulators to sell a near-replica of the blockbuster rheumatoid arthritis drug Enbrel in Europe, marking an early milestone for South Korea's biggest conglomerate in the nascent market for so-called biosimilar drugs. The approval comes as Samsung Bioepis Co... More...>>
01/16/20163:02AMDJNMerck Pays $830 Million To Settle Suit Over Vioxx Claims
(FROM THE WALL STREET JOURNAL 1/16/16) By Peter Loftus The painkiller Vioxx continues to pain Merck & Co. finances, more than 11 years after the company yanked the drug from the market because it increased users' risk of heart attacks and strokes. Merck said on Friday it agreed to pay $830 million to resolve a... More...>>
01/15/20163:55PMDJNGermany's Merck KGaA Wins Battle Over Name in U.K.
By Ulrike Dauer FRANKFURT--Germany's Merck KGaA said Friday it has won a U.K. court ruling that prevents U.S. drug company Merck & Co. Inc. from using the Merck name in the U.K. when doing business. But the dispute isn't over. Merck & Co. said it would appeal the U.K. court decision, and it filed a suit... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V:us D:20160210 04:46:53